Medtronic decides that Solitaire is best played with a partner.
One of the biggest drugs of the year, Abbvie’s Jak inhibitor upadacitinib, could get the nod in August.
The company has quietly emerged as the key player to watch in an area that has seen several setbacks of late.
In the wake of a clinical trial failure Marinus plays down oral ganaxolone, but investors are unimpressed.
Acadia has tried to see the positives after a pivotal trial failure with Nuplazid in schizophrenia, but the data bode ill for other label-expansion studies.
A strong second quarter pushed Novartis’s stock up 5% this morning, but Kymriah continues to look weak, and the jury is still out on Zolgensma.
Neon Therapeutics is due to unveil the first rigorous test of its neoantigen approach to fighting tumours, while Neurotrope makes a brave bid in Alzheimer's.
Weaker than expected generic erosion of its key Suboxone film product has allowed Indivior to raise full-year guidance.
Probiodrug changes its name to Vivoryon and expands its focus to include oncology, but insists that it is still first and foremost an Alzheimer’s company.